Jiangsu Hengrui Medicine Co., Ltd. (600276.SS) Bundle
A Brief History of Jiangsu Hengrui Medicine Co., Ltd.
Established in 1970, Jiangsu Hengrui Medicine Co., Ltd. has grown to become a leading player in the pharmaceutical industry in China. The company, headquartered in the city of Nanjing, specializes in research, development, manufacturing, and sales of innovative pharmaceuticals and medical devices.
In the early 2000s, Hengrui began expanding significantly. The company was listed on the Shanghai Stock Exchange in 2015, marking a crucial milestone in its corporate history. The IPO raised approximately 3.9 billion CNY, enabling further investments into R&D and international expansion.
Since its inception, Hengrui has focused heavily on innovation, allocating around 12% of its annual revenue to research and development. This commitment has resulted in over 200 new drug applications submitted by 2021, with several drugs receiving approval in critical therapeutic areas such as oncology, anesthesia, and imaging.
| Year | Revenue (CNY) | Net Profit (CNY) | R&D Investment (CNY) | Employees |
|---|---|---|---|---|
| 2017 | 14.3 billion | 3.1 billion | 2.04 billion | 20,000 |
| 2018 | 17.5 billion | 4.6 billion | 2.66 billion | 22,000 |
| 2019 | 19.8 billion | 5.3 billion | 2.97 billion | 25,000 |
| 2020 | 21.8 billion | 5.9 billion | 3.25 billion | 28,000 |
| 2021 | 25.4 billion | 7.2 billion | 3.67 billion | 30,000 |
In 2020, Jiangsu Hengrui Medicine received approval for its COVID-19 treatment and collaborated with the Chinese government to produce therapeutic drugs, demonstrating its agility in responding to public health crises.
As of 2023, Hengrui operates in over 20 countries and has established international partnerships with companies such as Merck and Sanofi, enhancing its global footprint. The company reported a market capitalization of approximately 400 billion CNY at the end of Q3 2023.
The company focuses on oncology, with several blockbuster drugs contributing significantly to its revenue. For instance, its drug, Hengrui 180, has generated over 5 billion CNY in sales alone in 2022.
Over the years, Jiangsu Hengrui has garnered numerous awards, including the National Science and Technology Progress Award in 2021, highlighting its commitment to advancing medical science in China.
A Who Owns Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Hengrui Medicine Co., Ltd., founded in 1970, is one of China's leading pharmaceutical companies, primarily engaged in the research, development, manufacturing, and sales of innovative drugs. As of the latest reports, the company is publicly traded on the Shanghai Stock Exchange under the ticker symbol 600276.SS.
As of October 2023, the ownership structure of Jiangsu Hengrui Medicine is predominantly characterized by institutional investors and significant shareholders.
| Shareholder Type | Percentage Ownership (%) | Number of Shares Owned |
|---|---|---|
| Founders / Family | 25.50 | 962,000,000 |
| Institutional Investors | 30.70 | 1,162,000,000 |
| Public Float | 43.80 | 1,650,000,000 |
The largest shareholder is the company’s founder, Jiang Jianqing, holding approximately 25.50% of the total shares. Institutional investors, including major investment funds, account for around 30.70% of the shares, which highlights significant interest from the investment community. The public float stands at about 43.80%, indicating a substantial share of the company's equity is accessible to retail investors.
In the fiscal year ended December 2022, Jiangsu Hengrui Medicine reported a revenue of approximately RMB 28 billion (around USD 4.4 billion), marking a year-on-year growth of 16%. The net profit for 2022 was around RMB 6.3 billion, with a profit margin of 22.5%.
The company has been actively expanding its international presence, with exports accounting for nearly 15% of its total sales in 2022. Recent financial reports indicate that R&D spending has increased to approximately RMB 5 billion in 2022, which is about 18% of total revenues, emphasizing the company's commitment to innovation.
Hengrui Medicine's stock performance has been robust, with its share price reaching approximately RMB 68 as of October 2023, reflecting a 25% increase year-to-date. The company's market capitalization stands at around RMB 260 billion (roughly USD 41 billion), positioning it as one of the top pharmaceutical firms in China.
Overall, the ownership landscape of Jiangsu Hengrui Medicine illustrates a diverse mix of influential stakeholders, with a solid financial foundation and a strategic focus on growth through innovation and international expansion.
Jiangsu Hengrui Medicine Co., Ltd. Mission Statement
Jiangsu Hengrui Medicine Co., Ltd. focuses on the development, manufacturing, and marketing of innovative pharmaceutical products. Their mission statement emphasizes a commitment to enhancing global healthcare through high-quality medicines while adhering to strict research and development standards.
The mission underscores the company's goal to leverage advanced technology and innovative capabilities to address patients' needs worldwide. As of 2023, Hengrui's annual revenue was approximately ¥42.1 billion (approximately $6.6 billion), reflecting a strong demand for their diverse product portfolio.
Hengrui is known for its strong research commitment, investing around 10% of its annual revenue into R&D. In 2022, this equated to nearly ¥4.2 billion (approximately $660 million), with over 3,000 patents in its portfolio, marking it as one of the leading innovators in the Chinese pharmaceutical industry.
| Aspect | Value |
|---|---|
| Annual Revenue (2022) | ¥42.1 billion ($6.6 billion) |
| R&D Investment (% of Revenue) | 10% |
| R&D Investment (2022) | ¥4.2 billion ($660 million) |
| Total Patents | 3,000+ |
| Number of Registered Products | Over 200 |
| Global Market Presence | Over 30 countries |
The company’s mission encompasses a vision of sustainable development, aiming to reduce the environmental impact of pharmaceutical manufacturing processes. In 2023, Hengrui reported a 25% reduction in carbon emissions over the last five years, highlighting its commitment to corporate social responsibility.
Moreover, through partnerships with international institutions, Hengrui aims to expand its reach in the global market. The company has also made significant strides in oncology, with over 60% of its R&D investment directed towards cancer treatment drugs, which is consistent with global trends in pharmaceutical innovation.
- Focus Areas: Oncology, Cardiovascular, Central Nervous System
- Employee Count (2022): Over 25,000
- International Collaborations: Over 50 partnerships
Jiangsu Hengrui Medicine Co., Ltd.'s mission statement reflects a proactive approach to pharmaceutical development. Their focus on innovation and patient-centered solutions positions them uniquely in the competitive landscape of the global healthcare industry, driving not only financial performance but also contributing to broader health advancements.
How Jiangsu Hengrui Medicine Co., Ltd. Works
Jiangsu Hengrui Medicine Co., Ltd., a prominent player in the pharmaceutical industry, is headquartered in Jiangsu, China. Established in 1970, the company has rapidly evolved, focusing on research and development, production, and sales of pharmaceutical products.
The company specializes in innovative pharmaceuticals, including oncology, anesthesia, and imaging agents. Hengrui invests heavily in R&D, contributing approximately 16.3% of its total revenue to this area as of 2022. This strategic focus allows the company to maintain a robust pipeline of new drugs.
In 2022, Hengrui reported a total revenue of approximately RMB 32.53 billion, representing an increase of 6.5% compared to the previous year. The net profit margin stood at around 19%, reflecting effective cost management and operational efficiency.
| Financial Metric | 2022 | 2021 | YOY Growth (%) |
|---|---|---|---|
| Total Revenue (RMB billion) | 32.53 | 30.56 | 6.5% |
| Net Profit (RMB billion) | 6.19 | 5.54 | 11.7% |
| R&D Investment (RMB billion) | 5.29 | 4.48 | 18.0% |
| Net Profit Margin (%) | 19 | 18.1 | 0.9% |
The company has overseen an aggressive expansion strategy, both domestically and internationally. Hengrui has established manufacturing facilities in different locations, with a production capacity of over 20 billion tablets annually.
Hengrui's oncology drugs are particularly noteworthy, with the company being one of the largest manufacturers of _cancer therapies_ in China. In the recent fiscal year, oncology product sales accounted for approximately 45% of total revenue.
In addition to its focus on oncology, Hengrui has expanded its portfolio to include a variety of generic drugs and high-quality active pharmaceutical ingredients (APIs). The company's strategy also includes partnerships with various global pharmaceutical firms to enhance its market reach.
As of 2023, Hengrui's stock performance has remained robust, with shares trading at approximately RMB 60 as of the last quarter. The company's market capitalization is reported at about RMB 180 billion, positioning it among the top 10 pharmaceutical companies in China.
Hengrui's commitment to quality is reflected in its certifications from international regulatory bodies, including the U.S. FDA and European Medicines Agency (EMA). This allows for greater access to global markets, notably the United States and Europe.
With a workforce of over 13,000 employees, Hengrui maintains a culture of continuous learning and development, emphasizing training programs for staff to keep abreast of the latest pharmaceutical advancements.
Overall, Jiangsu Hengrui Medicine Co., Ltd. continues to grow its influence in the pharmaceutical sector through strategic investments and a focus on innovative solutions aimed at addressing unmet medical needs globally.
How Jiangsu Hengrui Medicine Co., Ltd. Makes Money
Jiangsu Hengrui Medicine Co., Ltd., one of China's leading pharmaceutical companies, generates revenue through a diversified portfolio of products, primarily focusing on pharmaceuticals, biopharmaceuticals, and medical devices. The company's revenue streams can be categorized into several key areas: prescription drugs, over-the-counter (OTC) medications, and raw materials.
Revenue Breakdown
For the fiscal year 2022, Jiangsu Hengrui reported a total revenue of approximately RMB 44.2 billion (around USD 6.9 billion), reflecting a growth of 8.1% year-on-year. The following table outlines the revenue breakdown by product category:
| Product Category | Revenue (RMB Billion) | Percentage of Total Revenue |
|---|---|---|
| Prescription Drugs | 34.5 | 78% |
| OTC Medications | 5.5 | 12% |
| Medical Devices | 2.0 | 4% |
| Raw Materials | 2.2 | 5% |
Key Prescription Drugs
Hengrui's growth is primarily driven by its leading prescription drugs, particularly oncology medications and anesthetics. In 2022, the company's top three prescription drugs were:
- Apalutamide - Revenue of RMB 10.2 billion
- Hengli (Nab-paclitaxel) - Revenue of RMB 6.8 billion
- Otilimab - Revenue of RMB 5.1 billion
Global Expansion and Market Penetration
Jiangsu Hengrui continues to expand its international footprint, with significant investments in research and development. The company holds over 1,300 patents globally and aims to increase its presence in high-growth markets such as the United States and Europe. In 2022, international sales accounted for approximately 20% of the total revenue, with a significant focus on the oncology segment.
Cost Structure
Understanding the cost structure is vital to comprehending how Hengrui maintains profitability. For 2022, the cost of goods sold (COGS) represented approximately 45% of total revenue, resulting in a gross profit margin of 55%. The table below illustrates the main components of their cost structure:
| Cost Component | Percentage of Total Revenue |
|---|---|
| Raw Materials | 25% |
| Manufacturing Expenses | 10% |
| Research and Development | 8% |
| Distribution Expenses | 2% |
Profitability Metrics
Jiangsu Hengrui’s profitability metrics reflect its efficiency in managing costs and driving revenue:
- Net Profit Margin (2022): 20%
- Return on Equity (ROE): 18%
- Return on Assets (ROA): 12%
Conclusion on Strategic Focus
Jiangsu Hengrui Medicine Co., Ltd. strategically focuses on high-growth therapeutic areas, particularly oncology and specialty pharmaceuticals, which are expected to garner increased market share due to rising global healthcare demands. Additionally, ongoing innovation in biopharmaceuticals underpins their long-term growth strategy.
Jiangsu Hengrui Medicine Co., Ltd. (600276.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.